202 related articles for article (PubMed ID: 26581144)
1. Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.
Wolden SL; Lyden ER; Arndt CA; Hawkins DS; Anderson JR; Rodeberg DA; Morris CD; Donaldson SS
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1071-6. PubMed ID: 26581144
[TBL] [Abstract][Full Text] [Related]
2. Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
Casey DL; Chi YY; Donaldson SS; Hawkins DS; Tian J; Arndt CA; Rodeberg DA; Routh JC; Lautz TB; Gupta AA; Yock TI; Wolden SL
Cancer; 2019 Sep; 125(18):3242-3248. PubMed ID: 31174239
[TBL] [Abstract][Full Text] [Related]
3. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
Arndt CA; Stoner JA; Hawkins DS; Rodeberg DA; Hayes-Jordan AA; Paidas CN; Parham DM; Teot LA; Wharam MD; Breneman JC; Donaldson SS; Anderson JR; Meyer WH
J Clin Oncol; 2009 Nov; 27(31):5182-8. PubMed ID: 19770373
[TBL] [Abstract][Full Text] [Related]
4. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group.
Smith LM; Anderson JR; Qualman SJ; Crist WM; Paidas CN; Teot LA; Pappo AS; Link MP; Grier HE; Wiener ES; Breneman JC; Raney RB; Maurer HM; Donaldson SS
J Clin Oncol; 2001 Oct; 19(20):4058-64. PubMed ID: 11600608
[TBL] [Abstract][Full Text] [Related]
5. Parameningeal rhabdomyosarcoma: outcomes and opportunities.
Yang JC; Wexler LH; Meyers PA; Wolden SL
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e61-6. PubMed ID: 23021437
[TBL] [Abstract][Full Text] [Related]
6. Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma.
Buszek SM; Ludmir EB; Grosshans DR; McAleer MF; McGovern SL; Harrison DJ; Okcu MF; Chintagumpala MM; Mahajan A; Paulino AC
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):718-725. PubMed ID: 33516439
[TBL] [Abstract][Full Text] [Related]
7. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Hawkins DS; Chi YY; Anderson JR; Tian J; Arndt CAS; Bomgaars L; Donaldson SS; Hayes-Jordan A; Mascarenhas L; McCarville MB; McCune JS; McCowage G; Million L; Morris CD; Parham DM; Rodeberg DA; Rudzinski ER; Shnorhavorian M; Spunt SL; Skapek SX; Teot LA; Wolden S; Yock TI; Meyer WH
J Clin Oncol; 2018 Sep; 36(27):2770-2777. PubMed ID: 30091945
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
Rodeberg DA; Garcia-Henriquez N; Lyden ER; Davicioni E; Parham DM; Skapek SX; Hayes-Jordan AA; Donaldson SS; Brown KL; Triche TJ; Meyer WH; Hawkins DS
J Clin Oncol; 2011 Apr; 29(10):1304-11. PubMed ID: 21357792
[TBL] [Abstract][Full Text] [Related]
9. Does debulking improve survival rate in advanced-stage retroperitoneal embryonal rhabdomyosarcoma?
Blakely ML; Lobe TE; Anderson JR; Donaldson SS; Andrassy RJ; Parham DM; Wharam MD; Qualman SJ; Wiener ES; Grier HE; Crist WM
J Pediatr Surg; 1999 May; 34(5):736-41; discussion 741-2. PubMed ID: 10359174
[TBL] [Abstract][Full Text] [Related]
10. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Raney RB; Walterhouse DO; Meza JL; Andrassy RJ; Breneman JC; Crist WM; Maurer HM; Meyer WH; Parham DM; Anderson JR
J Clin Oncol; 2011 Apr; 29(10):1312-8. PubMed ID: 21357783
[TBL] [Abstract][Full Text] [Related]
11. Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas.
Chen C; Shu HK; Goldwein JW; Womer RB; Maity A
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1294-9. PubMed ID: 12654440
[TBL] [Abstract][Full Text] [Related]
12. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
[TBL] [Abstract][Full Text] [Related]
13. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.
Baker KS; Anderson JR; Link MP; Grier HE; Qualman SJ; Maurer HM; Breneman JC; Wiener ES; Crist WM
J Clin Oncol; 2000 Jun; 18(12):2427-34. PubMed ID: 10856103
[TBL] [Abstract][Full Text] [Related]
14. Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from The Intergroup Rhabdomyosarcoma Study-IV, 1991-1997.
Raney RB; Stoner JA; Walterhouse DO; Andrassy RJ; Donaldson SS; Laurie F; Meyer WH; Qualman SJ; Crist WM;
Pediatr Blood Cancer; 2004 Jun; 42(7):618-25. PubMed ID: 15127417
[TBL] [Abstract][Full Text] [Related]
15. The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803.
Spalding AC; Hawkins DS; Donaldson SS; Anderson JR; Lyden E; Laurie F; Wolden SL; Arndt CA; Michalski JM
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):512-6. PubMed ID: 24074925
[TBL] [Abstract][Full Text] [Related]
16. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV.
Michalski JM; Meza J; Breneman JC; Wolden SL; Laurie F; Jodoin M; Raney B; Wharam MD; Donaldson SS
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1027-38. PubMed ID: 15234036
[TBL] [Abstract][Full Text] [Related]
17. Patterns of failure and toxicity profile following proton beam therapy for pediatric bladder and prostate rhabdomyosarcoma.
Buszek SM; Ludmir EB; Grosshans DR; McAleer MF; McGovern SL; Harrison DJ; Okcu MF; Chintagumpala MM; Mahajan A; Paulino AC
Pediatr Blood Cancer; 2019 Nov; 66(11):e27952. PubMed ID: 31397065
[TBL] [Abstract][Full Text] [Related]
18. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
Meza JL; Anderson J; Pappo AS; Meyer WH;
J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
[TBL] [Abstract][Full Text] [Related]
19. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.
Bisogno G; De Salvo GL; Bergeron C; Gallego Melcón S; Merks JH; Kelsey A; Martelli H; Minard-Colin V; Orbach D; Glosli H; Chisholm J; Casanova M; Zanetti I; Devalck C; Ben-Arush M; Mudry P; Ferman S; Jenney M; Ferrari A;
Lancet Oncol; 2019 Nov; 20(11):1566-1575. PubMed ID: 31562043
[TBL] [Abstract][Full Text] [Related]
20. Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.
Breneman J; Meza J; Donaldson SS; Raney RB; Wolden S; Michalski J; Laurie F; Rodeberg DA; Meyer W; Walterhouse D; Hawkins DS
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):720-6. PubMed ID: 22104356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
